IMPURITY: Internal Limiting Membrane Peeling in Retinal Detachment Surgery

Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05538156
Collaborator
(none)
126
2
63

Study Details

Study Description

Brief Summary

Despite advances in surgical techniques over the recent decades, proliferative vitreoretinopathy (PVR) remains the main obstacle to successful rhegmatogenous retinal detachment (RRD) repair, accounting for nearly 75% of all primary surgical failures. It is characterized by the growth and contraction of cellular membranes within the vitreous cavity and on both surfaces of the detached retina as well as intraretinal fibrosis.

The Retina Society classification, modified in 1991 and currently the most widely used, divided PVR into three grades. Grade A is limited to the presence of vitreous haze and pigment clumps. Grade B includes rolled or irregular edges of tear and/or inner retinal surface wrinkling with possible retinal stiffness and vessel tortuosity. Grade C is defined as the presence of full-thickness fixed retinal folds and is further subdivided based on the number of hours involved and the location.

Recently, Foveau et al., in a retrospective comparative case series, have demonstrated that performing internal limiting membrane (ILM) peeling during RRD surgery may increase the anatomical success rate for this indication.

The aim of this multi-center, prospective, randomized controlled clinical trial study is to evaluate the effectiveness of ILM peeling on surgical outcomes in patients with primary macula-off RRD complicated by grade B PVR.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Control group
  • Procedure: Intervention group
N/A

Detailed Description

Despite advances in surgical techniques over the recent decades, proliferative vitreoretinopathy (PVR) remains the main obstacle to successful rhegmatogenous retinal detachment (RRD) repair, accounting for nearly 75% of all primary surgical failures. It is characterized by the growth and contraction of cellular membranes within the vitreous cavity and on both surfaces of the detached retina as well as intraretinal fibrosis.

The Retina Society classification, modified in 1991 and currently the most widely used, divided PVR into three grades. Grade A is limited to the presence of vitreous haze and pigment clumps. Grade B includes rolled or irregular edges of tear and/or inner retinal surface wrinkling with possible retinal stiffness and vessel tortuosity. Grade C is defined as the presence of full-thickness fixed retinal folds and is further subdivided based on the number of hours involved and the location.

Grade B PVR is thought to represent an immature form of PVR with a definite potential for progression to further stages of PVR. Specific treatment for moderate PVR seems to be essential to halt the disease process and to reduce the risk of postoperative re-detachment. However, there is currently no consensus regarding the management of grade PVR. In macula-off RRD, vitrectomy with gas tamponade is often used as a primary option, with a retinal reattachment rate of 60%.

Recently, Foveau et al., in a retrospective comparative case series, have demonstrated that performing internal limiting membrane (ILM) peeling during RRD surgery may increase the anatomical success rate for this indication.

The aim of this multi-center, prospective, randomized controlled clinical trial study is to evaluate the effectiveness of ILM peeling on surgical outcomes in patients with primary macula-off RRD complicated by grade B PVR.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
126 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Internal Limiting Membrane Peeling in Macula-off Retinal Detachment With Grade B Proliferative Vitreoretinopathy
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2026
Anticipated Study Completion Date :
Dec 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Other: Control group

The internal limiting membrane is not removed

Procedure: Control group
Vitrectomy and gas tamponade without internal limiting membrane peeling

Other: Intervention group

The internal limiting membrane of the posterior pole is removed

Procedure: Intervention group
Vitrectomy, internal limiting membrane peeling and gas tamponade

Outcome Measures

Primary Outcome Measures

  1. Primary anatomical success rate [12 months after surgery]

    Primary retinal reattachment rate

Secondary Outcome Measures

  1. Functional outcomes #1 [12 months after surgery]

    Visual acuity (Logarithm of the Minimum Angle of Resolution)

  2. Functional outcomes #2 [12 months after surgery]

    Degree of metamorphopsia (M-CHARTS)

  3. Anatomical outcomes #1 [12 months after surgery]

    Integrity of the photoreceptor layer on Spectral Domain Optical Coherence Tomography

  4. Anatomical outcomes #2 [12 months after surgery]

    Incidence of epiretinal membrane

  5. Anatomical outcomes #3 [12 months after surgery]

    Incidence of cystoid macular edema

  6. Anatomical outcomes #4 [12 months after surgery]

    Incidence of DONFL appearance

  7. Functional outcomes #3 [12 months after surgery]

    Retinal sensitivity on microperimetry testing

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients older than 18 years old

  • With macula-off retinal detachment complicated by grade B proliferative vitreoretinopathy

Exclusion Criteria:
  • Underage patients

  • History of retinal detachment

  • History of intraocular surgery (except for cataract surgery)

  • Traumatic retinal detachment

  • Macular hole-associated retinal detachment

  • Concurrent macular disease (diabetic maculopathy, age-related macular degeneration)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Central Hospital, Nancy, France

Investigators

  • Principal Investigator: Jean-Baptiste CONART, Prof, Brabois Hospital, Nancy, France

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT05538156
Other Study ID Numbers:
  • 2022-A00665-38
First Posted:
Sep 13, 2022
Last Update Posted:
Sep 13, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 13, 2022